<DOC>
	<DOCNO>NCT01225393</DOCNO>
	<brief_summary>This Phase II , randomize , double-blind , placebo-controlled , parallel-group , multicenter study enrol patient active rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety MLTA3698A Combination With Disease-Modifying Anti-Rheumatic Drug ( DMARD ) Compared With Adalimumab Combination With DMARD Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis RA accord 1987 revised ACR Criteria Classification RA least 6 month prior screen Positive rheumatoid factor anticyclic citrullinated peptide ( CCP ) antibody , Active disease , define : CRP &gt; = 1.0 mg/dL ; swell joint count &gt; = 6 ( 66 joint count ) ; tender joint count &gt; = 6 ( 68 joint count ) Previous inadequate clinical response least one diseasemodifying antirheumatic drug ( DMARD ) consist either methotrexate ( MTX ) leflunomide ( LFU ) For patient currently receive corticosteroid : Treatment stable dose last 4 week prior screen For patient currently receive nonsteroidal antiinflammatory drug ( NSAIDs ) : Treatment stable dose last 4 week prior screen For patient currently receive sulfasalazine antimalarial : Treatment initiate continue least last 6 month prior screen stable dose For patient reproductive potential ( male female ) : Willing use highly effective birth control method duration study accord local guideline Pregnant , plan become pregnant study , breastfeed Clinically significant abnormal laboratory value abnormal ECG vital sign History anaphylactic reaction Rheumatic autoimmune disease RA , significant systemic involvement secondary RA ( include limit vasculitis , pulmonary fibrosis , Felty 's syndrome ) , however patient secondary Sjogren 's syndrome eligible study History current inflammatory joint disease RA ( e.g. , gout , reactive arthritis , psoriatic arthritis , seronegative spondyloarthritis , Lyme disease ) systemic autoimmune disorder ( e.g. , systemic lupus erythematosus , inflammatory bowel disease , scleroderma , inflammatory myopathy , mixed connective tissue disease , overlap syndrome ) Current recent ( within 4 week prior screen ) infection , include sign , symptom serology infection , include HIV , hepatitis B C , tuberculosis Administration live , attenuate vaccine within 1 month dose anticipation live attenuated vaccine require study Previous treatment antiTNF biologics biologic agent , include antiCD20directed therapy ( e.g . rituximab ) , antiIL6directed therapy ( e.g . tocilizumab ) , T celldirected therapy ( e.g . abatacept )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>